Aspirin and clopidogrel resistance: Methodological challenges and opportunities

Vascular Health and Risk Management

Volumn 6, Issue 1, 2010, Pages 109-112

  Gasparyan, Armen Yuri ^a  

^a RUSSELLS HALL HOSPITAL   (United Kingdom)

Author keywords

Aspirin; Cardiovascular disease; Clopidogrel; Platelet function tests; Resistance

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; CYCLOOXYGENASE 1; PRASUGREL; VASODILATOR STIMULATED PHOSPHOPROTEIN;

ANALYZER; ARTICLE; BLOOD CLOTTING PARAMETERS; BLOOD CLOTTING TEST; CARDIOVASCULAR DISEASE; DIAGNOSTIC ACCURACY; DRUG MONITORING; FLOW CYTOMETRY; HUMAN; PREVALENCE; SHEAR STRESS; THROMBOCYTE AGGREGATION INHIBITION; THROMBOCYTE FUNCTION; THROMBOCYTE VOLUME; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 77950796980     PISSN: 11766344     EISSN: 11782048     Source Type: Journal    
DOI: 10.2147/vhrm.s9087     Document Type: Article

References (20)

1. Antithrombotic Trialists' Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ. 2002;324(7329):71-86.
2. Gasparyan AY, Watson T, Lip GY. The role of aspirin in cardiovascular prevention: implications of aspirin resistance. J Am Coll Cardiol. 2008;51(19):1829-1843.
3. Wang ZJ, Zhou YJ, Liu YY, et al. Impact of clopidogrel resistance on thrombotic events after percutaneous coronary intervention with drug-eluting stent. Thromb Res. 2009;124(1):46-51.
4. Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW, Huisman MV. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J. 2007;154(2):221-231.
5. Schwartz KA, Schwartz DE, Barber K, Reeves M, De Franco AC. Noncompliance is the predominant cause of aspirin resistance in chronic coronary arterial disease patients. J Transl Med. 2008;6:46.
6. Cox D, Maree AO, Dooley M, Conroy R, Byrne MF, Fitzgerald DJ. Effect of enteric coating on antiplatelet activity of low-dose aspirin in healthy volunteers. Stroke. 2006;37(8):2153-2158.
7. Modica A, Karlsson F, Mooe T. Platelet aggregation and aspirin nonresponsiveness increase when an acute coronary syndrome is complicated by an infection. J Thromb Haemost. 2007;5(3):507-511.
8. Sharma RK, Reddy HK, Singh VN, Sharma R, Voelker DJ, Bhatt G. Aspirin and clopidogrel hyporesponsiveness in patients with coronary artery stenting. Vasc Health Risk Manag. 2009;5:965-972.
9. Cattaneo M. Laboratory detection of 'aspirin resistance': what test should we use (if any)? Eur Heart J. 2007;28(14):1673-1675.
10. Lordkipanidzé M, Pharand C, Schampaert E, Turgeon J, Palisaitis DA, Diodati JG. A comparison of six major platelet function tests to determine the prevalence of aspirin resistance in patients with stable coronary artery disease. Eur Heart J. 2007;28(14):1702-1708.
11. Lordkipanidzé M, Pharand C, Nguyen TA, Schampaert E, Palisaitis DA, Diodati JG. Comparison of four tests to assess inhibition of platelet function by clopidogrel in stable coronary artery disease patients. Eur Heart J. 2008;29(23):2877-2885.
12. Gasparyan A, Blann A, Watson T, Lip G. Platelet function in coronary artery disease: defining response to antiplatelets [abstract]. Atherosclerosis Suppl. 2008;9(1):209.
13. Sanioglu S, Tetik S, Sokullu O, et al. Aspirin resistance after CABG. Thorac Cardiovasc Surg. 2009;57(5):281-285.
14. Aksu H, Ozer O, Unal H, et al. Significance of mean platelet volume on prognosis of patients with and without aspirin resistance in settings of non-ST-segment elevated acute coronary syndromes. Blood Coagul Fibrinolysis. 2009 Aug 27. [Epub ahead of print].
15. Erhart S, Beer JH, Reinhart WH. Influence of aspirin on platelet count and volume in humans. Acta Haematol. 1999;101(3):140-144.
16. Huczek Z, Filipiak KJ, Kochman J, et al. Baseline platelet size is increased in patients with acute coronary syndromes developing early stent thrombosis and predicts future residual platelet reactivity. A casecontrol study. Thromb Res. 2009 Sep 26. [Epub ahead of print].
17. Gum PA, Kottke-Marchant K, Welsh PA, White J, Topol EJ. A prospective, blinded determination of the natural history of aspirin resistance among stable patients with cardiovascular disease. J Am Coll Cardiol. 2003;41(6):961-965.
18. Ruef J, Kranzhöfer R. Coronary stent thrombosis related to aspirin resistance: what are the underlying mechanisms? J Interv Cardiol. 2006;19(6):507-509.
19. Zimmermann N, Gams E, Hohlfeld T. Aspirin in coronary artery bypass surgery: new aspects of and alternatives for an old antithrombotic agent. Eur J Cardiothorac Surg. 2008;34(1):93-108.
20. Wiviott SD, Braunwald E, McCabe CH, et al; TRITON-TIMI 38 Investigators. Intensive oral antiplatelet therapy for reduction of ischaemic events including stent thrombosis in patients with acute coronary syn-dromes treated with percutaneous coronary intervention and stenting in the TRITON-TIMI 38 trial: a subanalysis of a randomised trial. Lancet. 2008;371(9621):1353-1363.